An update on the pharmacotherapeutic management of lower respiratory tract infections
- 19 May 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 18 (10) , 973-988
Abstract
Introduction: Our knowledge about lower respiratory tract infections (LRTIs) has improved substantially in the last years, but the management of respiratory infections is still a challenge and we are still far from using precision medicine in their treatment. Areas covered: The approaches developed in recent years to improve the pharmacotherapeutic management of LRTIs, such as novel diagnostic assays to facilitate medical decision-making, attempts for selecting an optimal empiric antibiotic regimen, and the role of new and possibly unproven adjunctive therapies, are described. Expert opinion: Early and appropriate antibiotics remain the cornerstone in the treatment of LRTIs. The updated trend is to apply antimicrobial stewardship principles and initiatives to optimize both the management and the outcomes of LTRIs. Biomarkers, mainly C-reactive protein (CRP) and procalcitonin (PCT), can improve the diagnostic and prognostic assessment of LRTIs and aid to guide antibiotic therapy. The widespread use of antimicrobial agents has greatly contributed to faster development of antibiotic resistance and the emergence of opportunistic pathogens, which substitute the indigenous microbiota. However, very few new antibiotics in development to overcome existing resistance and ensure continued success in the treatment of LRTIs have been approved, likely because antibiotic stewardship programs discourage the use of new agents.Keywords
This publication has 131 references indexed in Scilit:
- Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary diseaseJournal of Allergy and Clinical Immunology, 2013
- Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumoniaRespiratory Medicine, 2012
- Copeptin in the assessment of acute lung injury and cardiogenic pulmonary edemaRespiratory Medicine, 2012
- Ecology and Evolution as Targets: the Need for Novel Eco-Evo Drugs and Strategies To Fight Antibiotic ResistanceAntimicrobial Agents and Chemotherapy, 2011
- Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trialRespiratory Research, 2010
- Duration of antibiotic therapy in hospitalised patients with community-acquired pneumoniaEuropean Respiratory Journal, 2009
- Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen unteren Atemwegsinfektionen sowie ambulant erworbener Pneumonie – Update 2009Pneumologie, 2009
- Effects of glucocorticoids in ventilated piglets with severe pneumoniaEuropean Respiratory Journal, 2008
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Improvement of Process‐of‐Care and Outcomes after Implementing a Guideline for the Management of Community‐Acquired Pneumonia: A Controlled Before‐and‐After Design StudyClinical Infectious Diseases, 2004